Rolofylline flunks Phase III

Merck will not file an application for regulatory approval of rolofylline in 2009 as initially planned because a pivotal study of the adenosine A1 receptor antagonist failed to meet its primary or secondary efficacy endpoints. Merck had thought the drug had potential to be the first major acute heart failure therapy that preserves renal function and improves outcomes after an earlier pilot study showed an overall trend toward efficacy (1Start-Up, September 2007). Merck said June 5 that rolofylline did no better than placebo in the 2,033-patient PROTECT study in improving symptoms of acute heart failure, nor did it reduce the risk of death or cardiovascular or renal re-hospitalization versus placebo by 60 days after treatment. Merck plans to present more explicit results at a meeting later this year. Rolofylline was not expected to be a big seller, but the loss of yet another Phase III compound, particularly a cardiovascular drug, is a blow for Merck - and drives home the rationale for its merger with Schering-Plough (2"The Pink Sheet," March 16, 2009, p. 18)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.